---

Stephen T. Colgan

Senior Director, Global CMC, Pfizer Worldwide Research and Development

Dr. Colgan has advocated lean stability strategies for more than a decade. These strategies provide a focus on the highest risk attributes and time points and facilitate rapid introduction of medicines into clinical trials. Regulatory filings are more science and risk-based without impacting safety, efficacy, or quality of the product.

---

Part of the Power List 2016

The Top 100

The nominations are in and after considerable debate and analysis from our judging panel, we present The Power List 2016 – our second foray into the Top 100 most influential people in the world of drug development and manufacture.

Go to The Power List 2016